{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:49:24Z","timestamp":1765381764566,"version":"3.40.3"},"publisher-location":"Berlin, Heidelberg","reference-count":114,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783642218910"},{"type":"electronic","value":"9783642218927"}],"license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.1007\/978-3-642-21892-7_3","type":"book-chapter","created":{"date-parts":[[2012,1,2]],"date-time":"2012-01-02T12:24:59Z","timestamp":1325507099000},"page":"65-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Bisphosphonates: Prevention of Bone Metastases in Breast Cancer"],"prefix":"10.1007","author":[{"given":"Michael","family":"Gnant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dubsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyman","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,3]]},"reference":[{"key":"3_CR1","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.exphem.2009.04.008","volume":"37","author":"Y Abe","year":"2009","unstructured":"Abe Y, Muto M, Nieda M et al (2009) Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 37:956\u2013968","journal-title":"Exp Hematol"},{"issue":"suppl 5","key":"3_CR2","doi-asserted-by":"publisher","first-page":"v9","DOI":"10.1093\/annonc\/mdq159","volume":"21","author":"S Aebi","year":"2010","unstructured":"Aebi S, Davidson T, Gruber G et al (2010) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl 5):v9\u2013v14","journal-title":"Ann Oncol"},{"key":"3_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","volume":"11","author":"R Aft","year":"2010","unstructured":"Aft R, Naughton M, Trinkaus K et al (2010) Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 11:421\u2013428","journal-title":"Lancet Oncol"},{"key":"3_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/1477-3163.75723","volume":"10","author":"H Almubarak","year":"2011","unstructured":"Almubarak H, Jones A, Chaisuparat R et al (2011) Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog 10:2","journal-title":"J Carcinog"},{"key":"3_CR5","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","volume":"359","author":"M Baum","year":"2002","unstructured":"Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131\u20132139","journal-title":"Lancet"},{"key":"3_CR6","volume-title":"Bonefos [summary of product characteristics]","author":"Bayer Plc","year":"2010","unstructured":"Bayer Plc (2010) Bonefos [summary of product characteristics]. Bayer Plc, Newbury"},{"key":"3_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1138\/20100450","volume":"7","author":"I Benzaid","year":"2010","unstructured":"Benzaid I, Clezardin P (2010) Nitrogen-containing bisphosphonates and human \u03b3\u03b4 T cells. IBMS BoneKEy 7:208\u2013217","journal-title":"IBMS BoneKEy"},{"key":"3_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.10-1-52","volume":"10","author":"JR Berenson","year":"2005","unstructured":"Berenson JR (2005) Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10:52\u201362","journal-title":"Oncologist"},{"key":"3_CR9","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1093\/annonc\/mdp200","volume":"20","author":"FC Bidard","year":"2009","unstructured":"Bidard FC, Kirova YM, Vincent-Salomon A et al (2009) Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer. Ann Oncol 20:1836\u20131841","journal-title":"Ann Oncol"},{"key":"3_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/annonc\/mdm507","volume":"19","author":"FC Bidard","year":"2008","unstructured":"Bidard FC, Vincent-Salomon A, Sigal-Zafrani B et al (2008) Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 19:496\u2013500","journal-title":"Ann Oncol"},{"key":"3_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0093-7754(01)90232-5","volume":"28","author":"JJ Body","year":"2001","unstructured":"Body JJ (2001) Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 28:49\u201353","journal-title":"Semin Oncol"},{"key":"3_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","volume":"13","author":"A Brufsky","year":"2008","unstructured":"Brufsky A, Bundred N, Coleman R et al (2008) Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13:503\u2013514","journal-title":"Oncologist"},{"issue":"suppl 1","key":"3_CR13","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1053\/j.seminoncol.2010.06.002","volume":"37","author":"AM Brufsky","year":"2010","unstructured":"Brufsky AM (2010) The evolving role of bone-conserving therapy in patients with breast cancer. Semin Oncol 37(suppl 1):S12\u2013S19","journal-title":"Semin Oncol"},{"key":"3_CR14","first-page":"1404","volume":"276","author":"JA Cauley","year":"1996","unstructured":"Cauley JA, Lucas FL, Kuller LH et al (1996) Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 276:1404\u20131408","journal-title":"Study of Osteoporotic Fractures Research Group. JAMA"},{"key":"3_CR15","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/cncr.23674","volume":"113","author":"Z Chen","year":"2008","unstructured":"Chen Z, Arendell L, Aickin M et al (2008) Hip bone density predicts breast cancer risk independently of Gail score: results from the Women\u2019s Health Initiative. Cancer 113:907\u2013915","journal-title":"Cancer"},{"key":"3_CR16","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1200\/JCO.2010.28.2095","volume":"28","author":"RT Chlebowski","year":"2010","unstructured":"Chlebowski RT, Chen Z, Cauley JA et al (2010) Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582\u20133590","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"3_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2005.09.002","volume":"31","author":"P Clezardin","year":"2005","unstructured":"Clezardin P (2005) Anti-tumour activity of zoledronic acid. Cancer Treat Rev 31(suppl 3):1\u20138","journal-title":"Cancer Treat Rev"},{"key":"3_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1749-6632.2010.05766.x","volume":"1218","author":"R Coleman","year":"2011","unstructured":"Coleman R (2011) The use of bisphosphonates in cancer treatment. Ann N Y Acad Sci 1218:3\u201314","journal-title":"Ann N Y Acad Sci"},{"key":"3_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176","journal-title":"Cancer Treat Rev"},{"issue":"suppl 4","key":"3_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","volume":"9","author":"RE Coleman","year":"2004","unstructured":"Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(suppl 4):14\u201327","journal-title":"Oncologist"},{"key":"3_CR21","doi-asserted-by":"crossref","unstructured":"Coleman R, Bundred N, de Boer R et al (2009) Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST [poster]. Presented at: 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, 9\u201313 Dec 2009 Abstract 4082","DOI":"10.1158\/0008-5472.SABCS-09-4082"},{"key":"3_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ctrv.2010.04.003","volume":"36","author":"RE Coleman","year":"2010","unstructured":"Coleman RE, Lipton A, Roodman GD et al (2010a) Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev 36:615\u2013620","journal-title":"Cancer Treat Rev"},{"key":"3_CR23","doi-asserted-by":"crossref","unstructured":"Coleman RE, Thorpe HC, Cameron D et al (2010b) Adjuvant treatment with zoledronic acid in stage II\/III breast cancer. The AZURE trial (BIG 01\/04) [oral presentation]. Presented at 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, 8\u201312 Dec 2010 Abstract S4-5","DOI":"10.1158\/0008-5472.SABCS10-S4-5"},{"key":"3_CR24","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","volume":"102","author":"RE Coleman","year":"2010","unstructured":"Coleman RE, Winter MC, Cameron D et al (2010c) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102:1099\u20131105","journal-title":"Br J Cancer"},{"key":"3_CR25","doi-asserted-by":"crossref","unstructured":"Coleman R, Costa L, Saad F et al (2011a) Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol [Epub ahead of print]","DOI":"10.1016\/j.critrevonc.2011.02.005"},{"key":"3_CR26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-011-1429-y","volume":"127","author":"R Coleman","year":"2011b","unstructured":"Coleman R, Woodward E, Brown J et al (2011b) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II\/III breast cancer. Breast Cancer Res Treat 127:429\u2013438","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 1","key":"3_CR27","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/S1040-8428(11)70006-3","volume":"77","author":"L Costa","year":"2011","unstructured":"Costa L, Harper P, Coleman RE et al (2011) Anticancer evidence for zoledronic acid across the cancer continuum. Crit Rev Oncol Hematol 77(suppl 1):S31\u2013S37","journal-title":"Crit Rev Oncol Hematol"},{"key":"3_CR28","doi-asserted-by":"crossref","unstructured":"de Boer R, Bundred N, Eidtmann H et al (2010) The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up [poster]. Presented at: 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, 8\u201312 Dec 2010 Abstract P5-11-01","DOI":"10.1158\/0008-5472.SABCS10-P5-11-01"},{"key":"3_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1023\/A:1005792830054","volume":"43","author":"L Del Mastro","year":"1997","unstructured":"Del Mastro L, Venturini M, Sertoli MR et al (1997) Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 43:183\u2013190","journal-title":"Breast Cancer Res Treat"},{"key":"3_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2184.2011.00745.x","volume":"44","author":"M Di Salvatore","year":"2011","unstructured":"Di Salvatore M, Orlandi A, Bagala C et al (2011) Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 44:139\u2013146","journal-title":"Cell Prolif"},{"key":"3_CR31","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","volume":"19","author":"IJ Diel","year":"2008","unstructured":"Diel IJ, Jaschke A, Solomayer EF et al (2008) Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 19:2007\u20132011","journal-title":"Ann Oncol"},{"key":"3_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/annonc\/mdn554","volume":"20","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Kastritis E, Bamia C et al (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117\u2013120","journal-title":"Ann Oncol"},{"key":"3_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.maturitas.2006.11.012","volume":"57","author":"T Douchi","year":"2007","unstructured":"Douchi T, Yonehara Y, Kosha S et al (2007) Bone mineral density in breast cancer patients with positive estrogen receptor tumor status. Maturitas 57:221\u2013225","journal-title":"Maturitas"},{"key":"3_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1084\/jem.20110132","volume":"208","author":"A Ehninger","year":"2011","unstructured":"Ehninger A, Trumpp A (2011) The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med 208:421\u2013428","journal-title":"J Exp Med"},{"key":"3_CR35","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","volume":"21","author":"H Eidtmann","year":"2010","unstructured":"Eidtmann H, de Boer R, Bundred N et al (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 21:2188\u20132194","journal-title":"Ann Oncol"},{"key":"3_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000087286","volume":"69","author":"G Ferretti","year":"2005","unstructured":"Ferretti G, Fabi A, Carlini P et al (2005) Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69:35\u201343","journal-title":"Oncology"},{"key":"3_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","volume":"9","author":"JF Forbes","year":"2008","unstructured":"Forbes JF, Cuzick J, Buzdar A et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45\u201353","journal-title":"Lancet Oncol"},{"key":"3_CR36","unstructured":"Garcia M, Jemal A, Ward EM et al. (2007) Global Cancer Facts & Figures 2007. American Cancer Society, Atlanta"},{"key":"3_CR39","first-page":"85","volume":"107","author":"B Gerber","year":"2010","unstructured":"Gerber B, Freund M, Reimer T (2010) Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int 107:85\u201391","journal-title":"Dtsch Arztebl Int"},{"key":"3_CR40","doi-asserted-by":"publisher","first-page":"824","DOI":"10.2174\/156800909789760267","volume":"9","author":"M Gnant","year":"2009","unstructured":"Gnant M (2009) Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets 9:824\u2013833","journal-title":"Curr Cancer Drug Targets"},{"key":"3_CR41","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840\u2013849","journal-title":"Lancet Oncol"},{"key":"3_CR42","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679\u2013691","journal-title":"N Engl J Med"},{"key":"3_CR43","doi-asserted-by":"crossref","unstructured":"Gnant M, Mlineritsch B, Stoeger H et al (2010) Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer [poster]. Presented at: 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, 4\u20138 June 2010 Abstract 533","DOI":"10.1200\/jco.2010.28.15_suppl.533"},{"key":"3_CR44","doi-asserted-by":"crossref","unstructured":"Gnant M, Mlineritsch B, Stoeger H et al (2011) Preplanned subgroup analysis of ABCSG-12 suggests that benefits of adjuvant zoledronic acid (ZOL) are most pronounced in lowest estrogen environment [poster]. Presented at: 12th St. Gallen International Breast Cancer Conference, St Gallen, Switzerland, 16\u201319 March 2011 Abstract P286","DOI":"10.1016\/S0960-9776(11)70228-4"},{"issue":"suppl 3","key":"3_CR45","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2009.0076","volume":"7","author":"JR Gralow","year":"2009","unstructured":"Gralow JR, Biermann JS, Farooki A et al (2009) NCCN Task Force report: bone health in cancer care. J Natl Compr Canc Netw 7(suppl 3):S1\u2013S32 quiz S33-S35","journal-title":"J Natl Compr Canc Netw"},{"key":"3_CR46","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3109\/07357907.2010.512598","volume":"28","author":"J Green","year":"2010","unstructured":"Green J, Lipton A (2010) Anticancer properties of zoledronic acid. Cancer Invest 28:944\u2013957","journal-title":"Cancer Invest"},{"issue":"suppl 4","key":"3_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","volume":"9","author":"JR Green","year":"2004","unstructured":"Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9(suppl 4):3\u201313","journal-title":"Oncologist"},{"issue":"suppl 1","key":"3_CR48","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S1040-8428(11)70003-8","volume":"77","author":"JR Green","year":"2011","unstructured":"Green JR, Guenther A (2011) The backbone of progress\u2014preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol 77(suppl 1):S3\u2013S12","journal-title":"Crit Rev Oncol Hematol"},{"issue":"15 suppl","key":"3_CR49","first-page":"114s","volume":"28","author":"S Greenberg","year":"2010","unstructured":"Greenberg S, Park JW, Melisko ME et al (2010) Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): updated results [abstract]. J Clin Oncol 28(15 suppl):114s Abstract 1002","journal-title":"J Clin Oncol"},{"key":"3_CR50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1210\/er.19.1.18","volume":"19","author":"TA Guise","year":"1998","unstructured":"Guise TA, Mundy GR (1998) Cancer and bone. Endocr Rev 19:18\u201354","journal-title":"Endocr Rev"},{"key":"3_CR51","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","volume":"19","author":"P Hadji","year":"2008","unstructured":"Hadji P, Body JJ, Aapro MS et al (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19:1407\u20131416","journal-title":"Ann Oncol"},{"key":"3_CR52","doi-asserted-by":"crossref","unstructured":"Hadji P, Aapro MS, Body JJ et al (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol (Epub ahead of print)","DOI":"10.1093\/annonc\/mdr017"},{"key":"3_CR53","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/DDDT.S6287","volume":"4","author":"RC Hamdy","year":"2010","unstructured":"Hamdy RC (2010) Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Des Devel Ther 4:321\u2013335","journal-title":"Drug Des Devel Ther"},{"key":"3_CR54","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","volume":"139","author":"RE Hewitt","year":"2005","unstructured":"Hewitt RE, Lissina A, Green AE et al (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139:101\u2013111","journal-title":"Clin Exp Immunol"},{"key":"3_CR55","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042\u20134057","journal-title":"J Clin Oncol"},{"key":"3_CR56","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1359\/jbmr.080205","volume":"23","author":"AO Hoff","year":"2008","unstructured":"Hoff AO, Toth BB, Altundag K et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826\u2013836","journal-title":"J Bone Miner Res"},{"key":"3_CR57","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1158\/1078-0432.CCR-10-2515","volume":"17","author":"WJ Janni","year":"2011","unstructured":"Janni WJ, Vogl FD, Wiedswang G et al (2011) Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse\u2014a European pooled analysis. Clin Cancer Res 17:2967\u20132976","journal-title":"Clin Cancer Res"},{"key":"3_CR58","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106\u2013130","journal-title":"CA Cancer J Clin"},{"key":"3_CR59","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","volume":"139","author":"MY Kim","year":"2009","unstructured":"Kim MY, Oskarsson T, Acharyya S et al (2009) Tumor self-seeding by circulating cancer cells. Cell 139:1315\u20131326","journal-title":"Cell"},{"key":"3_CR60","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314\u20133321","journal-title":"J Clin Oncol"},{"key":"3_CR61","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1080\/02841860801964988","volume":"47","author":"B Kristensen","year":"2008","unstructured":"Kristensen B, Ejlertsen B, Mouridsen HT et al (2008) Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 47:740\u2013746","journal-title":"Acta Oncol"},{"key":"3_CR62","doi-asserted-by":"crossref","unstructured":"Lin AY, Park JW, Scott J et al (2008) Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [abstract]. J Clin Oncol 26(15 suppl): 20s Abstract 559","DOI":"10.1200\/jco.2008.26.15_suppl.559"},{"key":"3_CR63","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-010-0935-7","volume":"122","author":"A Lipton","year":"2010","unstructured":"Lipton A (2010) Should bisphosphonates be utilized in the adjuvant setting for breast cancer? Breast Cancer Res Treat 122:627\u2013636","journal-title":"Breast Cancer Res Treat"},{"key":"3_CR64","unstructured":"Lipton A, Chapman JW, Demers L et al (2009) Elevated bone resorption predicts shorter recurrence-free survival for bone metastasis in breast cancer [poster]. Presented at: Primary Therapy of Early Breast Cancer 11th International Conference, St. Gallen, Switzerland, 11\u201314 March 2009 Abstract 244"},{"key":"3_CR65","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/oxfordjournals.aje.a009554","volume":"148","author":"FL Lucas","year":"1998","unstructured":"Lucas FL, Cauley JA, Stone RA et al (1998) Bone mineral density and risk of breast cancer: differences by family history of breast cancer. Study of Osteoporotic Fractures Research Group. Am J Epidemiol 148:22\u201329","journal-title":"Am J Epidemiol"},{"key":"3_CR66","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","volume":"19","author":"P Major","year":"2001","unstructured":"Major P, Lortholary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558\u2013567","journal-title":"J Clin Oncol"},{"key":"3_CR67","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<6::AID-CNCR3>3.0.CO;2-D","volume":"88","author":"PP Major","year":"2000","unstructured":"Major PP, Lipton A, Berenson J et al (2000) Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer 88:6\u201314","journal-title":"Cancer"},{"key":"3_CR68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10549-008-0291-z","volume":"117","author":"J Mansell","year":"2009","unstructured":"Mansell J, Monypenny IJ, Skene AI et al (2009) Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat 117:91\u201398","journal-title":"Breast Cancer Res Treat"},{"key":"3_CR69","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10549-009-0432-z","volume":"116","author":"D Mauri","year":"2009","unstructured":"Mauri D, Valachis A, Polyzos IP et al (2009) Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat 116:433\u2013439","journal-title":"Breast Cancer Res Treat"},{"key":"3_CR70","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","volume":"14","author":"MB Meads","year":"2008","unstructured":"Meads MB, Hazlehurst LA, Dalton WS (2008) The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 14:2519\u20132526","journal-title":"Clin Cancer Res"},{"key":"3_CR71","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584\u2013593","journal-title":"Nat Rev Cancer"},{"key":"3_CR72","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.molonc.2007.03.004","volume":"1","author":"B Naume","year":"2007","unstructured":"Naume B, Zhao X, Synnestvedt M et al (2007) Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol 1:160\u2013171","journal-title":"Mol Oncol"},{"issue":"suppl 1","key":"3_CR73","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1053\/j.seminoncol.2010.06.008","volume":"37","author":"HL Neville-Webbe","year":"2010","unstructured":"Neville-Webbe HL, Gnant M, Coleman RE (2010) Potential anticancer properties of bisphosphonates. Semin Oncol 37(suppl 1):S53\u2013S65","journal-title":"Semin Oncol"},{"key":"3_CR74","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/sj.bjc.6605555","volume":"102","author":"PA Newcomb","year":"2010","unstructured":"Newcomb PA, Trentham-Dietz A, Hampton JM (2010) Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102:799\u2013802","journal-title":"Br J Cancer"},{"key":"3_CR75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3233\/BD-2008-29104","volume":"29","author":"L Norton","year":"2008","unstructured":"Norton L (2008) Cancer stem cells, self-seeding, and decremented exponential growth: theoretical and clinical implications. Breast Dis 29:27\u201336","journal-title":"Breast Dis"},{"key":"3_CR76","unstructured":"Novartis Pharmaceuticals Corporation (2008) Zometa (zoledronic acid) injection (package insert). Novartis Pharmaceuticals Corporation, East Hanover"},{"key":"3_CR77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/bcr415","volume":"4","author":"SS Padalecki","year":"2002","unstructured":"Padalecki SS, Guise TA (2002) Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Res 4:35\u201341","journal-title":"Breast Cancer Res"},{"key":"3_CR78","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","volume":"133","author":"S Paget","year":"1889","unstructured":"Paget S (1889) Secondary growths in cancer of breast. Lancet 133:571\u2013573","journal-title":"Lancet"},{"key":"3_CR79","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","volume":"20","author":"T Powles","year":"2002","unstructured":"Powles T, Paterson S, Kanis JA et al (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219\u20133224","journal-title":"J Clin Oncol"},{"key":"3_CR80","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1186\/bcr1384","volume":"8","author":"T Powles","year":"2006","unstructured":"Powles T, Paterson A, McCloskey E et al (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer (ISRCTN83688026). Breast Cancer Res 8:R13","journal-title":"Breast Cancer Res"},{"key":"3_CR81","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","volume":"20","author":"M Rabaglio","year":"2009","unstructured":"Rabaglio M, Sun Z, Price KN et al (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1\u201398 trial. Ann Oncol 20:1489\u20131498","journal-title":"Ann Oncol"},{"key":"3_CR82","first-page":"1807","volume":"30","author":"B Rack","year":"2010","unstructured":"Rack B, Juckstock J, Genss EM et al (2010) Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 30:1807\u20131813","journal-title":"Anticancer Res"},{"issue":"suppl 1","key":"3_CR83","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","volume":"34","author":"DM Reid","year":"2008","unstructured":"Reid DM, Doughty J, Eastell R et al (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group. Cancer Treat Rev 34(suppl 1):S3\u2013S18","journal-title":"Cancer Treat Rev"},{"key":"3_CR84","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1200\/JCO.2010.28.1113","volume":"28","author":"G Rennert","year":"2010","unstructured":"Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577\u20133581","journal-title":"J Clin Oncol"},{"key":"3_CR85","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1200\/JCO.2010.33.7485","volume":"29","author":"G Rennert","year":"2011","unstructured":"Rennert G, Pinchev M, Rennert HS et al (2011) Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 29:1146\u20131150","journal-title":"J Clin Oncol"},{"key":"3_CR86","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/annonc\/mdn526","volume":"20","author":"CI Ripamonti","year":"2009","unstructured":"Ripamonti CI, Maniezzo M, Campa T et al (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137\u2013145","journal-title":"Ann Oncol"},{"key":"3_CR87","volume-title":"Bondronat (package insert)","author":"Roche","year":"2006","unstructured":"Roche (2006) Bondronat (package insert). Roche, Welwyn Garden City"},{"key":"3_CR88","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1309\/AJCPJI7DEOLKCS6F","volume":"132","author":"JS Ross","year":"2009","unstructured":"Ross JS, Slodkowska EA (2009) Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol 132:237\u2013245","journal-title":"Am J Clin Pathol"},{"issue":"suppl 1","key":"3_CR89","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0960-9776(08)70002-X","volume":"17","author":"HS Rugo","year":"2008","unstructured":"Rugo HS (2008) The importance of distant metastases in hormone-sensitive breast cancer. Breast 17(suppl 1):S3\u2013S8","journal-title":"Breast"},{"key":"3_CR90","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/cncr.22991","volume":"110","author":"F Saad","year":"2007","unstructured":"Saad F, Lipton A, Cook R et al (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860\u20131867","journal-title":"Cancer"},{"key":"3_CR91","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/02841860410032885","volume":"43","author":"T Saarto","year":"2004","unstructured":"Saarto T, Vehmanen L, Virkkunen P et al (2004) Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43:650\u2013656","journal-title":"Acta Oncol"},{"key":"3_CR92","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1210\/jc.2010-1679","volume":"96","author":"RJ Santen","year":"2011","unstructured":"Santen RJ (2011) Clinical review: effect of endocrine therapies on bone in breast cancer patients. J Clin Endocrinol Metab 96:308\u2013319","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR93","first-page":"1080","volume":"8","author":"D Santini","year":"2002","unstructured":"Santini D, Vincenzi B, Avvisati G et al (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8:1080\u20131084","journal-title":"Clin Cancer Res"},{"key":"3_CR94","first-page":"2893","volume":"9","author":"D Santini","year":"2003","unstructured":"Santini D, Vincenzi B, Dicuonzo G et al (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893\u20132897","journal-title":"Clin Cancer Res"},{"key":"3_CR95","first-page":"1351","volume":"15","author":"D Santini","year":"2006","unstructured":"Santini D, Vincenzi B, Hannon RA et al (2006) Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol Rep 15:1351\u20131357","journal-title":"Oncol Rep"},{"key":"3_CR96","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","volume":"13","author":"D Santini","year":"2007","unstructured":"Santini D, Vincenzi B, Galluzzo S et al (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13:4482\u20134486","journal-title":"Clin Cancer Res"},{"key":"3_CR97","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1359-6349(07)70770-X","volume":"5","author":"N Schenk","year":"2007","unstructured":"Schenk N, Lombart A, Frassoladti A et al (2007) The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (Let) [abstract]. Eur J Cancer 5:186\u2013187 Abstract 2008","journal-title":"Eur J Cancer"},{"key":"3_CR98","doi-asserted-by":"publisher","first-page":"R1174","DOI":"10.1186\/bcr1360","volume":"7","author":"C Schindlbeck","year":"2005","unstructured":"Schindlbeck C, Kampik T, Janni W et al (2005) Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas. Breast Cancer Res 7:R1174\u2013R1185","journal-title":"Breast Cancer Res"},{"issue":"suppl 1","key":"3_CR99","first-page":"88s","volume":"69","author":"C Schindlbeck","year":"2009","unstructured":"Schindlbeck C, Rack B, Jueckstock J et al (2009) Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy\u2014translational research program of the German SUCCESS-trial [abstract]. Cancer Res 69(suppl 1):88s Abstract 303","journal-title":"Cancer Res"},{"issue":"suppl 2","key":"3_CR100","first-page":"170s","volume":"69","author":"EF Solomayer","year":"2009","unstructured":"Solomayer EF, Gebauer G, Hirnle P et al (2009) Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [abstract]. Cancer Res 69(suppl 2):170s\u2013171s Abstract 2048","journal-title":"Cancer Res"},{"key":"3_CR101","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","volume":"22","author":"A Sverrisdottir","year":"2004","unstructured":"Sverrisdottir A, Fornander T, Jacobsson H et al (2004) Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22:3694\u20133699","journal-title":"J Clin Oncol"},{"key":"3_CR102","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/annonc\/mdj105","volume":"17","author":"T Tanvetyanon","year":"2006","unstructured":"Tanvetyanon T, Stiff PJ (2006) Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17:897\u2013907","journal-title":"Ann Oncol"},{"key":"3_CR103","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00262-011-0974-x","volume":"60","author":"E Terpos","year":"2011","unstructured":"Terpos E, Dimopoulos MA (2011) Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications. Cancer Immunol Immunother 60:305\u2013317","journal-title":"Cancer Immunol Immunother"},{"key":"3_CR104","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","volume":"17","author":"RL Theriault","year":"1999","unstructured":"Theriault RL, Lipton A, Hortobagyi GN et al (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846\u2013854","journal-title":"J Clin Oncol"},{"key":"3_CR105","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1056\/NEJMoa052258","volume":"353","author":"B Thurlimann","year":"2005","unstructured":"Thurlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747\u20132757","journal-title":"N Engl J Med"},{"key":"3_CR106","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1479-828X.1996.tb02200.x","volume":"36","author":"G Uncu","year":"1996","unstructured":"Uncu G, Benderli S, Esmer A (1996) Pregnancy during gonadotrophin-releasing hormone agonist therapy. Aust N Z J Obstet Gynaecol 36:484\u2013485","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"3_CR107","unstructured":"US Food and Drug Administration (2009) Background document for meeting of Advisory Committee for Reproductive Health Drugs (August 13, 2009). Denosumab. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ReproductiveHealthDrugsAdvisoryCommittee\/UCM176595.pdf. Accessed 11 April 2011"},{"key":"3_CR108","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.4049\/jimmunol.0901085","volume":"183","author":"P Vantourout","year":"2009","unstructured":"Vantourout P, Mookerjee-Basu J, Rolland C et al (2009) Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen. J Immunol 183:3848\u20133857","journal-title":"J Immunol"},{"key":"3_CR109","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","volume":"24","author":"L Vehmanen","year":"2006","unstructured":"Vehmanen L, Elomaa I, Blomqvist C et al (2006) Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 24:675\u2013680","journal-title":"J Clin Oncol"},{"key":"3_CR110","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1089\/jir.2005.25.144","volume":"25","author":"B Vincenzi","year":"2005","unstructured":"Vincenzi B, Santini D, Dicuonzo G et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144\u2013151","journal-title":"J Interferon Cytokine Res"},{"key":"3_CR111","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2011.172","volume":"305","author":"R Voelker","year":"2011","unstructured":"Voelker R (2011) \u201cDisappointing\u201d trial results offer hope for older women with breast cancer. JAMA 305:765\u2013766","journal-title":"JAMA"},{"key":"3_CR112","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/CCO.0b013e328331c794","volume":"21","author":"MC Winter","year":"2009","unstructured":"Winter MC, Coleman RE (2009) Bisphosphonates in breast cancer: teaching an old dog new tricks. Curr Opin Oncol 21:499\u2013506","journal-title":"Curr Opin Oncol"},{"key":"3_CR113","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","volume":"34","author":"MC Winter","year":"2008","unstructured":"Winter MC, Holen I, Coleman RE (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453\u2013475","journal-title":"Cancer Treat Rev"},{"key":"3_CR114","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/jnci\/93.12.930","volume":"93","author":"JM Zmuda","year":"2001","unstructured":"Zmuda JM, Cauley JA, Ljung BM et al (2001) Bone mass and breast cancer risk in older women: differences by stage at diagnosis. J Natl Cancer Inst 93:930\u2013936","journal-title":"J Natl Cancer Inst"}],"container-title":["Recent Results in Cancer Research","Prevention of Bone Metastases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-21892-7_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T22:11:25Z","timestamp":1676758285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-21892-7_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"ISBN":["9783642218910","9783642218927"],"references-count":114,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-21892-7_3","relation":{},"ISSN":["0080-0015"],"issn-type":[{"type":"print","value":"0080-0015"}],"subject":[],"published":{"date-parts":[[2012]]},"assertion":[{"value":"3 January 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}